Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics, Moffitt Cancer Center to Collaborate on microRNA Cancer Diagnostics

NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics announced today that it has formed a three-year collaboration with the Moffitt Cancer Center to discover, develop, and commercialize a range of microRNA-based cancer tests.

The alliance combines Rosetta's expertise in developing and commercializing miRNA diagnostics with Moffitt's network of medical oncologists and pathologists, and will focus specifically on areas of unmet medical need.

Rosetta said it has agreed to fund research conducted by Moffitt investigators that aligns with its strategic focus. The company currently has four miRNA diagnostics on the market including ones for lung cancer, kidney cancer, mesothelioma, and determining the source of tumors of unknown origin.

Additional terms of the collaboration were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.